We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+14.94%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$100M
AUM Growth
+$13.3M
Cap. Flow
+$8.34M
Cap. Flow %
8.3%
Top 10 Hldgs %
64.92%
Holding
34
New
8
Increased
8
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
GBT
Global Blood Therapeutics, Inc.
GBT
+$6.56M
2
EVH icon
Evolent Health
EVH
+$3.29M
3
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.85M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$2.19M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$1.95M

Top Sells

Rank Stock Value
1
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$3.7M
2
EDIT icon
Editas Medicine
EDIT
+$2.95M
3
EPZM
Epizyme, Inc
EPZM
+$2.29M
4
DXCM icon
DexCom
DXCM
+$1.7M
5
GHDX
Genomic Health, Inc.
GHDX
+$1.36M

Sector Composition

Rank Sector Weight
1 Healthcare 79.78%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRS
26
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$908K 0.9%
+5,000
New +$908K
GNMX
27
DELISTED
Aevi Genomic Medicine Inc
GNMX
$472K 0.47%
+85,000
New +$446K
BIIB icon
28
Biogen
BIIB
$29.8B
– –
-5,000
Closed -$1.3M
EDIT icon
29
Editas Medicine
EDIT
$407M
– –
-85,470
Closed -$2.95M
EXAS
30
DELISTED
Exact Sciences
EXAS
– –
-60,000
Closed -$404K
ONC
31
BeOne Medicines Ltd
ONC
$32.6B
– –
-32,500
Closed -$953K
OXFD
32
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
– –
-20,000
Closed -$198K
GHDX
33
DELISTED
Genomic Health, Inc.
GHDX
– –
-55,000
Closed -$1.36M
MDSO
34
DELISTED
Medidata Solutions, Inc.
MDSO
– –
-10,000
Closed -$387K
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return
WGAM
Wilkinson Global Asset Management New York $1.31B AUM 17.03% 1-Year Est. Return
CRAM
Compass Rose Asset Management New York $1.33B AUM 2.38% 1-Year Est. Return

Casdin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Casdin Capital held 34 positions worth $100M, up 15% from $87.1M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Casdin Capital deployed $8.34M of net new capital in Q2 2016, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Evolent Health: 239,500 shares worth $4.6M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 85% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was MyoKardia, Inc. Common Stock, an estimated $3.7M trimmed.

  • Casdin Capital's largest Q2 2016 buy was Evolent Health: 239,500 shares worth $4.6M.
  • Casdin Capital added most to Global Blood Therapeutics, Inc. in Q2 2016, an estimated $6.56M increase.
  • Casdin Capital's biggest Q2 2016 reduction was MyoKardia, Inc. Common Stock, cutting an estimated $3.7M.
  • Casdin Capital fully exited Editas Medicine in Q2 2016, selling an estimated $2.95M.
  • Casdin Capital's ten largest holdings make up 65% of its $100M portfolio in Q2 2016.
  • Casdin Capital opened 8 new positions and closed 7 in Q2 2016.
  • Casdin Capital's portfolio value rose 15% quarter-over-quarter to $100M.

Based on Casdin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.